Status:
RECRUITING
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
Lead Sponsor:
Chung Shan Medical University
Collaborating Sponsors:
National Science and Technology Council
Conditions:
Mild Cognitive Impairment
Alzheimer Disease
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild...
Detailed Description
Alzheimer's disease (AD) is an aging-related disease and is considered to be a type 3 diabetes. Brain-derived neurotrophic factor (BDNF) is a potential therapeutic biomarker for AD. Studies have found...
Eligibility Criteria
Inclusion
- Clinical diagnosis of mild cognitive impairment (MCI).
- Clinical diagnosis of Alzheimer's Disease.
- MCI and AD patients with hyperglycemia ( Fasting glucose \>=100 mg/dL).
- MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance).
- Must be able to swallow tablets.
Exclusion
- Cancer patients.
- Severe heart, lung, liver, and kidney diseases.
- Severe disability or aphasia.
- Malnutrition (body weight changes \> 5% within one month).
- Using coenzyme Q10 supplements.
- Warfarin therapy.
Key Trial Info
Start Date :
December 26 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06040905
Start Date
December 26 2023
End Date
July 31 2026
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung Shan Medical University Hospital
Taichung, Taiwan